Targeted Sequencing Market to Grow with a CAGR of 11.02% through 2029
Rising technological
advancements and innovation is expected to drive the Global Targeted Sequencing
Market growth in the forecast period, 2025-2029.
According to TechSci
Research report, “Targeted Sequencing Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2029”, the Global Targeted
Sequencing Market stood at USD 3.51 Billion in 2023 and is anticipated to grow
with a CAGR of 11.02% in the forecast period, 2025-2029. Companion diagnostics,
leveraging biomarker-based tests to inform treatment decisions, are
increasingly prominent in the healthcare sector. Targeted sequencing plays a
critical role in companion diagnostics by identifying biomarkers linked to drug
response, treatment resistance, and disease progression. With the rise of
personalized medicine, there is a growing demand for targeted sequencing-based
companion diagnostics, especially in oncology, where accurate treatment
selection is crucial for enhancing patient outcomes.
Growing
investments in genomics research and development are fostering innovation in
the targeted sequencing market. Governments, academic institutions, and private
enterprises are dedicating significant resources to support genomics
initiatives focused on unraveling the genetic underpinnings of diseases,
uncovering new therapeutic targets, and advancing precision medicine. These
investments are spurring technological progress, driving down sequencing costs,
and broadening the range of applications for targeted sequencing across diverse
fields, including pharmacogenomics, agricultural genomics, and microbial
genomics.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Targeted Sequencing Market”
The Global Targeted
Sequencing market is segmented into product
type, target enrichment method, target
capture type, end users, application, regional distribution, and company.
Based on the
product type, the kits/panels and assays segment emerged as the dominant
segment in the Global Targeted Sequencing Market in 2023. The
increasing need for comprehensive genomic profiling in clinical diagnostics and
precision medicine has led to the widespread acceptance of targeted sequencing
panels and assays. These panels are meticulously crafted to pinpoint clinically
significant genes, mutations, and biomarkers linked to various diseases such as
cancer, genetic disorders, and infectious diseases. By concentrating on
specific genomic regions of interest, targeted sequencing panels and assays
facilitate the efficient identification of actionable variants, paving the way
for personalized treatment approaches.
Progressions in
sequencing chemistry, library preparation techniques, and bioinformatics
algorithms have bolstered the sensitivity, specificity, and accuracy of
targeted sequencing assays, further propelling their adoption in both research
and clinical environments. These technological enhancements have empowered
researchers to identify low-frequency mutations, rare genetic variants, and
structural rearrangements with heightened confidence, broadening the
applicability of targeted sequencing across a diverse array of applications.
Based on the Target
Capture Type, the Targeted DNA Sequencing segment emerged as the dominant
segment in the global targeted sequencing market in 2023. Targeted DNA
Sequencing offers a highly focused and efficient approach to interrogating
specific regions of interest within the genome. By selectively targeting known
genomic regions, such as exons, promoters, or regulatory elements, researchers
can achieve deep coverage and high-resolution sequencing data, facilitating the
detection of genetic variations, mutations, and structural rearrangements with
exceptional sensitivity and accuracy. Targeted DNA Sequencing is particularly
well-suited for studying genetic diseases, cancer, and inherited disorders,
where the identification of disease-causing mutations or biomarkers is crucial
for diagnosis, prognosis, and treatment selection. By focusing sequencing
efforts on relevant genomic regions associated with specific diseases or
traits, Targeted DNA Sequencing enables researchers and clinicians to
efficiently identify actionable variants and tailor personalized treatment
strategies.
Based on the
Application, the oncology segment emerged as the dominant segment in the global
targeted sequencing market in 2023. targeted sequencing has revolutionized
cancer genomics by enabling the comprehensive profiling of tumor genomes,
transcriptomes, and epigenomes. By identifying somatic mutations, copy number
variations, and gene fusions associated with cancer development and
progression, targeted sequencing facilitates the identification of actionable
biomarkers and therapeutic targets. This enables oncologists to personalize
treatment strategies, select appropriate targeted therapies, and monitor
treatment responses, leading to improved patient outcomes. Moreover, the
growing demand for precision medicine in oncology has fueled the adoption of
targeted sequencing-based companion diagnostics. These tests help identify
predictive biomarkers, such as mutations in oncogenes or tumor suppressor
genes, that can guide treatment decisions and predict responses to targeted
therapies or immunotherapies.
North America
emerged as the dominant region in the Global Targeted Sequencing Market in
2023, holding the largest market share. The presence of a highly developed
healthcare ecosystem and favorable regulatory environment in North America has
facilitated the adoption of targeted sequencing technologies in clinical
diagnostics and personalized medicine. Regulatory agencies, such as the U.S.
Food and Drug Administration (FDA) and Health Canada, provide clear guidelines
and frameworks for the development and approval of targeted sequencing-based
diagnostic tests and companion diagnostics, fostering innovation and
commercialization in the market. Additionally, North America benefits from a
strong network of industry players, including sequencing technology providers,
biotechnology companies, and diagnostic laboratories, which drive market growth
through research collaborations, product development, and commercialization
efforts. The region also attracts substantial investments in genomics research
and healthcare innovation, further fueling the expansion of the targeted
sequencing market.
Major companies
operating in Global Targeted Sequencing Market are:
- MGI Tech Co., Ltd
- GENEWIZ Inc
- Agilent
Technologies, Inc.
- Daicel Arbor
Biosciences
- Danaher Corporation
- Illumina, Inc.
- LGC Biosearch
Technologies
- Pacific Biosciences
of California Inc
- CD Genomics
- F. Hoffmann-La
Roche Ltd
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The
global Targeted Sequencing market is poised for significant expansion in the
forthcoming years. the increasing prevalence of genetic disorders and cancer
cases worldwide has heightened the demand for personalized medicine, where
targeted sequencing plays a crucial role in identifying specific genetic
variations and guiding treatment decisions. Secondly, advancements in
sequencing technologies, such as improved accuracy, reduced costs, and enhanced
scalability, are making targeted sequencing more accessible and practical for a
broader range of applications. Additionally, the rising adoption of targeted
sequencing in clinical diagnostics and drug development processes is likely to
contribute significantly to the market's growth trajectory in the coming years.”
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Targeted Sequencing Market - Global Industry Size, Share, Trends,
Competition, Opportunity, and Forecast, Segmented By Product Type (Kits/Panels
and Assays, Instruments and Other), By Target Enrichment Method (Amplicon
Sequencing, Hybridization Capture, and Others), By Target Capture Type
(Targeted DNA Sequencing ,Targeted RNA Sequencing and others), By
Application(Oncology, Infectious Diseases, Cardiovascular Diseases,
Reproductive Health, Rare Diseases, Neurological Disorders, Hereditary
Diseases, and Others), By End Users (Academic and Research Institution,
Pharmaceutical and Biotech Companies, Diagnostic & Clinical Laboratories
and Other), By Region, By Competition, 2019-2029F”, has evaluated the
future growth potential of Global Targeted Sequencing Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Targeted Sequencing Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com